PT  - JOURNAL ARTICLE
AU  - Shuman, Jill
ED  - Kay, Jonathan
TI  - Infliximab Biosimilar Appears Safe and Effective Compared with Infliximab for RA
DP  - 2014  01
TA  - MD Conference Express
PG  - 11--11
VI  - 14
IP  - 51
4099  - http://mdc.sagepub.com/content/14/51/11.1.short
4100  - http://mdc.sagepub.com/content/14/51/11.1.full
AB  - Because Tumor necrosis factor inhibitors (TNFis) are expensive, however, there is currently much interest in lower-cost biosimilars—biological products that are highly similar to a licensed reference biological product with no clinically meaningful differences in safety, potency, and purity. This article presents results of a phase 3, randomized, double-blind, active comparator trial of the biosimilar BOW015 to its reference drug infliximab in patients with active rheumatoid arthritis.